WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124487
CAS#: 2523043-21-0
Description: 90Y-Anditixafortide (90Y-Pentixather) is the therapeutic analogue of 68Ga-Pentixafor, to be used in metastasized patients showing tumors expressing CXCR4.
Hodoodo Cat#: H124487
Name: Yttrium (90Y) anditixafortide
CAS#: 2523043-21-0
Chemical Formula: C60H76IN14O14Y
Exact Mass: 1,432.38
Molecular Weight: 1,433.160
Elemental Analysis: C, 50.28; H, 5.35; I, 8.85; N, 13.68; O, 15.63; Y, 6.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: QQV3T7MU5Z; Yttrium (90Y) anditixafortide; UNII-QQV3T7MU5Z; Yttrium (90Y) anditixafortide [INN]; 2523043-21-0
IUPAC/Chemical Name: yttrium(III) 2,2',2''-(10-(2-((4-((3-(5-(3-((diaminomethylene)amino)propyl)-14-(4-hydroxy-3-iodobenzyl)-1-methyl-8-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)propyl)carbamoyl)benzyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
InChi Key: OCTDAUASUALIGQ-UHFFFAOYSA-K
InChi Code: InChI=1S/C60H79IN14O14.Y/c1-71-48(9-5-18-64-55(85)42-15-10-38(11-16-42)32-66-51(78)34-72-20-22-73(35-52(79)80)24-26-75(37-54(83)84)27-25-74(23-21-72)36-53(81)82)58(88)69-45(8-4-19-65-60(62)63)57(87)70-46(30-39-12-14-41-6-2-3-7-43(41)28-39)56(86)67-33-50(77)68-47(59(71)89)31-40-13-17-49(76)44(61)29-40;/h2-3,6-7,10-17,28-29,45-48,76H,4-5,8-9,18-27,30-37H2,1H3,(H,64,85)(H,66,78)(H,67,86)(H,68,77)(H,69,88)(H,70,87)(H,79,80)(H,81,82)(H,83,84)(H4,62,63,65);/q;+3/p-3
SMILES Code: CN1C(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C1=O)CC2=CC(=C(C=C2)O)I)CC3=CC4=CC=CC=C4C=C3)CCCN=C(N)N)CCCNC(=O)C5=CC=C(C=C5)CNC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Y+3]
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 1,433.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A,
Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki
JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V,
Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C,
Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L,
Chatellier G; SARAH Trial Group. Efficacy and safety of selective internal
radiotherapy with yttrium-90 resin microspheres compared with sorafenib in
locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label
randomised controlled phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1624-1636.
doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. PMID: 29107679.
2: Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for
unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2020 Nov
16;11(11):CD011313. doi: 10.1002/14651858.CD011313.pub4. PMID: 33197051; PMCID:
PMC8215872.
3: Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L. Radioembolization,
Principles and indications. Nuklearmedizin. 2022 Jun;61(3):262-272. English.
doi: 10.1055/a-1759-4238. Epub 2022 Mar 30. PMID: 35354218.
4: Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J,
Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL,
Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH,
Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres
followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a
single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021
Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23. PMID:
34695377.
5: Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, Toskich B, Fowers K,
Herman JM, Kappadath SC, Leung T, Sze DY, Kim E, Garin E. Clinical, dosimetric,
and reporting considerations for Y-90 glass microspheres in hepatocellular
carcinoma: updated 2022 recommendations from an international multidisciplinary
working group. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):328-343. doi:
10.1007/s00259-022-05956-w. Epub 2022 Sep 17. PMID: 36114872; PMCID: PMC9816298.
6: Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E,
Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G,
Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S,
Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S,
Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus
standard dosimetry approach of selective internal radiation therapy in patients
with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised,
multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021
Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. PMID:
33166497.
7: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K,
Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of
Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021
Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11. PMID: 33739462;
PMCID: PMC8596669.
